Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

HEDIMED

Financiado

Human Exposomic Determinants of Immune Mediated Diseases

Immune-mediated diseases (IMDs) are increasing rapidly in the developed countries constituting a huge medical, economic and societal challenge. The reasons to this epidemic are not known, but exposome needs to play an important ro... ver más

31/12/2024

TAMPERE UNIVERSITY

12M€

Presupuesto del proyecto: 12M€

Líder del proyecto

TAMPEREEN KORKEAKOULUSAATIO SR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 25 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-06

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health

I+D

Cerrada hace 5 años

0% 100%

25 Participantes

TAMPERE UNIVERSITY

1.56M€ | Lider

ONMEDIC NETWORKS SL EN LIQUI...

816.04K€ | Participante

UNIVERSITY OF TURKU

1.16M€ | Participante

Proyectos interesantes

EUIN2015-62625 RED DE RE-CLASIFICACION MOLECULAR DE LAS ENFERMEDADES AUTOIN... 25K€ Cerrado

ImmRisk Defining how environmental factors influence downstream effe... 1M€ Cerrado

Long Covid Decision support for prediction and management of Long Covid... 7M€ Cerrado

PRECISESADS Molecular Reclassification to Find Clinically Useful Biomark... 23M€ Cerrado

SAF2009-08103 ESTIMULACION PAN-POBLACIONAL DE LA RESPUESTA DE LOS LINFOCIT... 88K€ Cerrado

IMCIS Individualised medicine in chronic inflammatory skin disease... 1M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-06
Fecha Fin: 2024-12-31

Líder del proyecto

TAMPEREEN KORKEAKOULUSAATIO SR

TRL 4-5

Presupuesto del proyecto 12M€

Descripción del proyecto Immune-mediated diseases (IMDs) are increasing rapidly in the developed countries constituting a huge medical, economic and societal challenge. The reasons to this epidemic are not known, but exposome needs to play an important role since genetic factors cannot explain such a rapid change. In the HEDIMED project altogether 20 academic and industrial partners will join their multidisciplinary and supplementary forces to identify exposomic determinants which are driving this epidemic. The project is based on a combination of data and biological samples from large clinical cohorts constituting the largest clinical resource in this field including 350.000 pregnant women, 28.000 children prospectively followed from birth and 6.600 children from cross-sectional studies. HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergies and asthma. Exposomic disease determinants and the underlying biological pathways will be identified by exploratory approach using advanced omics and multiplex technologies combined with cutting–edge datamining technologies. Particular emphasis is paid on early fetal and childhood exposome since the disease process is known to start early. Inclusion of several IMDs makes it possible to identify determinants that are common for many IMDs facilitating the development of widely operating treatments. HEDIMED includes also data and samples from clinical trials that have used exposomice interventions and cell and organ culture models to help the identification of causal associations. HEDIMED will generate an open-access toolbox that offers various kind of data, new technologies, interactions forums, latest information and functional tools for several stakeholders to facilitate the efforts to find ways to control the IMD epidemic. HEDIMED will generate several innovations which can become exploited widely in diagnostic, therapeutic, preventive and health-economical applications. HEDIMED will work together with the other projects (EXPANSE, HEAP, ATHLETE, EQUAL-LIFE, LONGITOOLS, EPHOR, REMEDIA and EXIMIOUS) funded within the Human Exposome programme call H2020 SC1-BHC-2018-2020, in order to achieve collaboration and synergy

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores